Seres Therapeutics Stock Price, News & Analysis (NASDAQ:MCRB)

$9.41 0.09 (0.97 %)
(As of 11/20/2017 04:12 AM ET)
Previous Close$9.32
Today's Range$9.10 - $9.62
52-Week Range$8.85 - $17.42
Volume185,500 shs
Average Volume211,000 shs
Market Capitalization$381.39 million
P/E RatioN/A
Dividend YieldN/A
Beta0.16

About Seres Therapeutics (NASDAQ:MCRB)

Seres Therapeutics logoSeres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI; SER-287 and SER-301, to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:MCRB
  • CUSIP: N/A
  • Web: www.serestherapeutics.com
Debt:
  • Debt-to-Equity Ratio: 0.11%
  • Current Ratio: 6.53%
  • Quick Ratio: 6.53%
Sales & Book Value:
  • Annual Sales: $21.77 million
  • Price / Sales: 17.52
  • Book Value: $3.29 per share
  • Price / Book: 2.86
Profitability:
  • Trailing EPS: ($2.12)
  • Net Income: ($91,570,000.00)
  • Net Margins: -267.15%
  • Return on Equity: -82.11%
  • Return on Assets: -36.25%
Misc:
  • Employees: 127
  • Outstanding Shares: 40,530,000
 

Frequently Asked Questions for Seres Therapeutics (NASDAQ:MCRB)

What is Seres Therapeutics' stock symbol?

Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."

How were Seres Therapeutics' earnings last quarter?

Seres Therapeutics, Inc. (NASDAQ:MCRB) issued its quarterly earnings results on Wednesday, November, 8th. The biotechnology company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.39) by $0.22. The biotechnology company had revenue of $23 million for the quarter, compared to analysts' expectations of $17.29 million. Seres Therapeutics had a negative net margin of 267.15% and a negative return on equity of 82.11%. The business's quarterly revenue was up 76.9% on a year-over-year basis. During the same period last year, the business earned ($0.46) earnings per share. View Seres Therapeutics' Earnings History.

Where is Seres Therapeutics' stock going? Where will Seres Therapeutics' stock price be in 2017?

9 Wall Street analysts have issued twelve-month price targets for Seres Therapeutics' shares. Their forecasts range from $16.00 to $20.00. On average, they expect Seres Therapeutics' stock price to reach $18.75 in the next twelve months. View Analyst Ratings for Seres Therapeutics.

What are Wall Street analysts saying about Seres Therapeutics stock?

Here are some recent quotes from research analysts about Seres Therapeutics stock:

  • 1. According to Zacks Investment Research, "Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (11/14/2017)
  • 2. Cowen and Company analysts commented, "Seres reported top-line results from a Phase 1b trial of SER-287 in 58 patients with." (10/2/2017)
  • 3. Canaccord Genuity analysts commented, "We believe that SER-109 Phase 2 trial study power was decreased by the inclusion of misdiagnosed and non-disease active patients. MCRB indicated that 72 of the 89 patients enrolled in the Phase 2 trials were chosen based on C. Difficile PCR diagnosis. A positive PCR test indicates that the cytotoxin gene is present, but does not directly indicate that the C. Difficile bacterium is producing the cytotoxin that causes the underlying symptoms. Thus a direct testing of cytotoxin is the most indicative of disease activity, and further qualifying stool samples analysis showed that only 15 of 31 PCR- positive samples were cytotoxin-positive. Importantly, Optimer utilized toxin testing for its fidaxomicin clinical program for recurrent C." (1/31/2017)

Who are some of Seres Therapeutics' key competitors?

Who are Seres Therapeutics' key executives?

Seres Therapeutics' management team includes the folowing people:

  • Roger Pomerantz M.D., Chairman of the Board, President, Chief Executive Officer (Age 60)
  • Eric D. Shaff, Chief Financial Officer, Executive Vice President (Age 41)
  • John G. Aunins Ph.D., Chief Technology Officer, Executive Vice President - Bioprocess and Manufacturing (Age 56)
  • David N. Cook Ph.D., Chief Scientific Officer, Executive Vice President - Research & Development (Age 59)
  • Thomas J. DesRosier J.D., Chief Legal Officer, Executive Vice President and Secretary (Age 62)
  • Michele Trucksis Ph.D. M.D., Chief Medical Officer and Executive Vice President (Age 64)
  • Noubar B. Afeyan, Lead Independent Director (Age 54)
  • Willard H. Dere M.D., Director (Age 63)
  • Dennis A. Ausiello M.D., Independent Director (Age 71)
  • Gregory Behar, Independent Director (Age 47)

When did Seres Therapeutics IPO?

(MCRB) raised $101 million in an IPO on Friday, June 26th 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

Who owns Seres Therapeutics stock?

Seres Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Artal Group S.A. (1.36%), JPMorgan Chase & Co. (0.92%), Perceptive Advisors LLC (0.33%), Schwab Charles Investment Management Inc. (0.25%), Schroder Investment Management Group (0.16%) and Ironwood Investment Management LLC (0.03%). Company insiders that own Seres Therapeutics stock include David N Cook, Eric D Shaff, John G Aunins, Michele Trucksis, Roger Pomerantz and Ventures Fund 2007 L Flagship. View Institutional Ownership Trends for Seres Therapeutics.

Who sold Seres Therapeutics stock? Who is selling Seres Therapeutics stock?

Seres Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A. and Advisor Group Inc.. View Insider Buying and Selling for Seres Therapeutics.

Who bought Seres Therapeutics stock? Who is buying Seres Therapeutics stock?

Seres Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, JPMorgan Chase & Co., Schroder Investment Management Group, Ironwood Investment Management LLC, Aperio Group LLC, Schwab Charles Investment Management Inc. and Cubist Systematic Strategies LLC. View Insider Buying and Selling for Seres Therapeutics.

How do I buy Seres Therapeutics stock?

Shares of Seres Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Seres Therapeutics' stock price today?

One share of Seres Therapeutics stock can currently be purchased for approximately $9.41.

How big of a company is Seres Therapeutics?

Seres Therapeutics has a market capitalization of $381.39 million and generates $21.77 million in revenue each year. The biotechnology company earns ($91,570,000.00) in net income (profit) each year or ($2.12) on an earnings per share basis. Seres Therapeutics employs 127 workers across the globe.

How can I contact Seres Therapeutics?

Seres Therapeutics' mailing address is 200 SIDNEY STREET 4TH FLOOR, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-945-9626.


MarketBeat Community Rating for Seres Therapeutics (NASDAQ MCRB)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  170 (Vote Outperform)
Underperform Votes:  127 (Vote Underperform)
Total Votes:  297
MarketBeat's community ratings are surveys of what our community members think about Seres Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Seres Therapeutics (NASDAQ:MCRB)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 9 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $18.75 (99.26% upside)

Consensus Price Target History for Seres Therapeutics (NASDAQ:MCRB)

Price Target History for Seres Therapeutics (NASDAQ:MCRB)

Analysts' Ratings History for Seres Therapeutics (NASDAQ:MCRB)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/13/2017CIBCInitiated CoverageOutperform -> Outperform$19.00N/AView Rating Details
10/12/2017Oppenheimer Holdings, Inc.Initiated CoverageOutperform$19.00N/AView Rating Details
10/12/2017Citigroup Inc.Initiated CoverageOutperform -> Positive$19.00N/AView Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$20.00N/AView Rating Details
10/2/2017Cowen and CompanyReiterated RatingBuyHighView Rating Details
8/30/2017Cantor FitzgeraldReiterated RatingBuyLowView Rating Details
8/4/2017HC WainwrightReiterated RatingBuy -> Buy$15.00 -> $19.00HighView Rating Details
8/3/2017Canaccord GenuitySet Price TargetBuy$20.00LowView Rating Details
3/20/2017FBR & CoReiterated RatingOutperform$18.00LowView Rating Details
8/11/2016Leerink SwannReiterated RatingBuy$12.00N/AView Rating Details
8/1/2016Bank of America CorporationDowngradeBuy -> NeutralN/AView Rating Details
3/3/2016GuggenheimInitiated CoverageBuy$41.00N/AView Rating Details
2/22/2016Goldman Sachs Group, Inc. (The)Lower Price Target$35.00 -> $34.00N/AView Rating Details
(Data available from 11/20/2015 forward)

Earnings

Earnings History and Estimates Chart for Seres Therapeutics (NASDAQ:MCRB)

Earnings by Quarter for Seres Therapeutics (NASDAQ:MCRB)

Earnings History by Quarter for Seres Therapeutics (NASDAQ MCRB)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3 2017($0.39)($0.17)$17.29 million$23.00 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.59)($0.69)$3.00 million$3.00 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.65)($0.63)$3.00 million$3.02 millionViewListenView Earnings Details
3/16/2017Q4 2016($0.70)($0.63)$3.00 million$3.00 millionViewN/AView Earnings Details
11/10/2016Q316($0.55)($0.46)$10.38 million$13.02 millionViewListenView Earnings Details
8/11/2016Q216($0.46)($0.70)$4.20 million$3.00 millionViewListenView Earnings Details
5/16/2016Q116($0.48)($0.50)$1.25 million$2.71 millionViewListenView Earnings Details
11/10/2015Q315($0.32)($0.38)ViewListenView Earnings Details
8/6/2015Q215($0.30)($1.45)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Seres Therapeutics (NASDAQ:MCRB)
2017 EPS Consensus Estimate: ($2.33)
2018 EPS Consensus Estimate: ($2.65)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.73)($0.53)($0.63)
Q2 20172($0.61)($0.50)($0.56)
Q3 20172($0.66)($0.23)($0.45)
Q4 20174($0.75)($0.68)($0.70)
Q1 20181($0.64)($0.64)($0.64)
Q2 20181($0.65)($0.65)($0.65)
Q3 20181($0.67)($0.67)($0.67)
Q4 20181($0.69)($0.69)($0.69)
Q1 20191($0.73)($0.73)($0.73)
Q2 20191($0.24)($0.24)($0.24)
Q3 20191($0.29)($0.29)($0.29)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Seres Therapeutics (NASDAQ:MCRB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Seres Therapeutics (NASDAQ MCRB)

Insider Ownership Percentage: 35.70%
Institutional Ownership Percentage: 77.04%
Insider Trades by Quarter for Seres Therapeutics (NASDAQ:MCRB)
Institutional Ownership by Quarter for Seres Therapeutics (NASDAQ:MCRB)

Insider Trades by Quarter for Seres Therapeutics (NASDAQ MCRB)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/29/2016John G AuninsInsiderSell9,390$10.87$102,069.30View SEC Filing  
7/28/2016Michele TrucksisInsiderSell4,156$35.18$146,208.08View SEC Filing  
7/27/2016Michele TrucksisInsiderSell38,064$35.14$1,337,568.96View SEC Filing  
7/25/2016John G AuninsInsiderSell9,390$34.18$320,950.20View SEC Filing  
7/6/2016Roger PomerantzCEOSell88,211$29.45$2,597,813.95View SEC Filing  
7/1/2016Roger PomerantzCEOSell56,789$29.81$1,692,880.09View SEC Filing  
6/30/2016Eric D ShaffCFOSell4,533$29.54$133,904.82View SEC Filing  
6/28/2016Eric D ShaffCFOSell5,001$28.28$141,428.28View SEC Filing  
6/27/2016John G AuninsEVPSell9,390$27.23$255,689.70View SEC Filing  
6/2/2016David N CookEVPSell8,000$31.00$248,000.00View SEC Filing  
6/2/2016Roger PomerantzCEOSell74,049$32.52$2,408,073.48View SEC Filing  
6/1/2016David N CookEVPSell16,000$29.43$470,880.00View SEC Filing  
6/1/2016Roger PomerantzCEOSell70,951$30.51$2,164,715.01View SEC Filing  
5/25/2016Ventures Fund 2007 L FlagshipMajor ShareholderSell1,000,000$27.60$27,600,000.00View SEC Filing  
5/24/2016Roger PomerantzCEOSell9,801$30.00$294,030.00View SEC Filing  
5/6/2016Roger PomerantzCEOSell8,507$24.31$206,805.17View SEC Filing  
5/5/2016Roger PomerantzCEOSell59,325$26.13$1,550,162.25View SEC Filing  
5/3/2016Roger PomerantzCEOSell67,367$28.70$1,933,432.90View SEC Filing  
4/25/2016John G AuninsEVPSell18,640$31.94$595,361.60View SEC Filing  
4/7/2016David N CookEVPSell8,000$31.00$248,000.00View SEC Filing  
4/7/2016Roger PomerantzCEOSell9,212$30.00$276,360.00View SEC Filing  
4/4/2016David N CookEVPSell61,000$26.16$1,595,760.00View SEC Filing  
4/4/2016Eric D ShaffCFOSell6,568$28.85$189,486.80View SEC Filing  
4/4/2016Roger PomerantzCEOSell135,788$27.20$3,693,433.60View SEC Filing  
3/31/2016Eric D ShaffCFOSell7,663$26.30$201,536.90View SEC Filing  
3/28/2016Eric D ShaffCFOSell5,473$24.07$131,735.11View SEC Filing  
3/28/2016John G AuninsEVPSell9,390$23.89$224,327.10View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Seres Therapeutics (NASDAQ MCRB)

Source:
DateHeadline
Seres Therapeutics, MD Anderson Cancer Center, and the Parker Institute for Cancer Immunotherapy Announce a Collaboration to Support the Investigation of Microbiome ...Seres Therapeutics, MD Anderson Cancer Center, and the Parker Institute for Cancer Immunotherapy Announce a Collaboration to Support the Investigation of Microbiome ...
www.businesswire.com - November 15 at 6:14 AM
Seres Therapeutics, MD Anderson Cancer Center, and the Parker Institute for Cancer Immunotherapy Announce a Collaboration to Support the Investigation of Microbiome Therapeutics for Immuno-OncologySeres Therapeutics, MD Anderson Cancer Center, and the Parker Institute for Cancer Immunotherapy Announce a Collaboration to Support the Investigation of Microbiome Therapeutics for Immuno-Oncology
finance.yahoo.com - November 15 at 6:14 AM
Seres teams up with MD Anderson to explore guts role in drug responseSeres teams up with MD Anderson to explore gut's role in drug response
finance.yahoo.com - November 15 at 6:14 AM
FY2017 Earnings Estimate for Seres Therapeutics, Inc. (MCRB) Issued By Oppenheimer HoldingsFY2017 Earnings Estimate for Seres Therapeutics, Inc. (MCRB) Issued By Oppenheimer Holdings
www.americanbankingnews.com - November 13 at 2:58 AM
FY2017 EPS Estimates for Seres Therapeutics, Inc. Lifted by Analyst (MCRB)FY2017 EPS Estimates for Seres Therapeutics, Inc. Lifted by Analyst (MCRB)
www.americanbankingnews.com - November 13 at 2:58 AM
Leerink Swann Weighs in on Seres Therapeutics, Inc.s FY2017 Earnings (MCRB)Leerink Swann Weighs in on Seres Therapeutics, Inc.'s FY2017 Earnings (MCRB)
www.americanbankingnews.com - November 13 at 2:58 AM
Edited Transcript of MCRB earnings conference call or presentation 8-Nov-17 1:00pm GMTEdited Transcript of MCRB earnings conference call or presentation 8-Nov-17 1:00pm GMT
finance.yahoo.com - November 8 at 10:22 PM
Seres Therapeutics Awarded Grant from CARB-X to Support Development of Microbiome Therapeutic Candidate - Business Wire (press release)Seres Therapeutics Awarded Grant from CARB-X to Support Development of Microbiome Therapeutic Candidate - Business Wire (press release)
www.businesswire.com - November 8 at 5:21 PM
Seres Therapeutics (MCRB) CEO Roger Pomerantz on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaSeres Therapeutics' (MCRB) CEO Roger Pomerantz on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 8 at 5:21 PM
Seres Therapeutics Awarded Grant from CARB-X to Support Development of Microbiome Therapeutic CandidateSeres Therapeutics Awarded Grant from CARB-X to Support Development of Microbiome Therapeutic Candidate
finance.yahoo.com - November 8 at 5:21 PM
Seres Therapeutics Reports Third Quarter 2017 Financial Results and Provides Update on Operational ProgressSeres Therapeutics Reports Third Quarter 2017 Financial Results and Provides Update on Operational Progress
finance.yahoo.com - November 8 at 5:21 PM
Seres Therapeutics reports 3Q lossSeres Therapeutics reports 3Q loss
finance.yahoo.com - November 8 at 5:21 PM
Seres Therapeutics to Participate in Three Upcoming November ConferencesSeres Therapeutics to Participate in Three Upcoming November Conferences
finance.yahoo.com - November 8 at 5:21 PM
Seres Therapeutics, Inc. (MCRB) Issues Quarterly  Earnings ResultsSeres Therapeutics, Inc. (MCRB) Issues Quarterly Earnings Results
www.americanbankingnews.com - November 8 at 2:39 PM
$18.01 Million in Sales Expected for Seres Therapeutics, Inc. (MCRB) This Quarter$18.01 Million in Sales Expected for Seres Therapeutics, Inc. (MCRB) This Quarter
www.americanbankingnews.com - November 7 at 4:16 AM
Zacks: Analysts Anticipate Seres Therapeutics, Inc. (MCRB) to Post -$0.40 EPSZacks: Analysts Anticipate Seres Therapeutics, Inc. (MCRB) to Post -$0.40 EPS
www.americanbankingnews.com - November 5 at 9:36 AM
Seres Therapeutics to Host Third Quarter 2017 Financial Results and Operational Progress Conference Call and Webcast on November 8, 2017Seres Therapeutics to Host Third Quarter 2017 Financial Results and Operational Progress Conference Call and Webcast on November 8, 2017
finance.yahoo.com - November 3 at 4:49 PM
Sigilon Therapeutics Appoints Eric Shaff to Board of DirectorsSigilon Therapeutics Appoints Eric Shaff to Board of Directors
finance.yahoo.com - November 2 at 6:16 AM
Seres Therapeutics, Inc. (MCRB) Scheduled to Post Quarterly Earnings on WednesdaySeres Therapeutics, Inc. (MCRB) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - November 1 at 4:50 AM
Seres Therapeutics, Inc. (MCRB) Receives Consensus Rating of "Buy" from BrokeragesSeres Therapeutics, Inc. (MCRB) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - November 1 at 3:32 AM
ETFs with exposure to Seres Therapeutics, Inc. : October 17, 2017ETFs with exposure to Seres Therapeutics, Inc. : October 17, 2017
finance.yahoo.com - October 18 at 6:52 AM
Benzingas Top Upgrades, Downgrades For October 13, 2017 - BenzingaBenzinga's Top Upgrades, Downgrades For October 13, 2017 - Benzinga
www.benzinga.com - October 14 at 2:51 AM
Seres Therapeutics, Inc. (MCRB) Research Coverage Started at CIBCSeres Therapeutics, Inc. (MCRB) Research Coverage Started at CIBC
www.americanbankingnews.com - October 13 at 10:22 AM
Seres Therapeutics, Inc. (MCRB) Coverage Initiated by Analysts at Oppenheimer Holdings, Inc.Seres Therapeutics, Inc. (MCRB) Coverage Initiated by Analysts at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - October 12 at 6:26 PM
Seres Therapeutics, Inc. (MCRB) Earns Positive Rating from Analysts at Citigroup Inc.Seres Therapeutics, Inc. (MCRB) Earns Positive Rating from Analysts at Citigroup Inc.
www.americanbankingnews.com - October 12 at 5:18 PM
Seaport Global Securities Begins Coverage on Seres Therapeutics, Inc. (MCRB)Seaport Global Securities Begins Coverage on Seres Therapeutics, Inc. (MCRB)
www.americanbankingnews.com - October 7 at 2:58 PM
Seres Therapeutics, Inc. (MCRB) Given Average Rating of "Buy" by BrokeragesSeres Therapeutics, Inc. (MCRB) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 7 at 4:52 AM
Seres Therapeutics Inc. (MCRB) Tumbled To A 2-Month Low On Study ResultsSeres Therapeutics Inc. (MCRB) Tumbled To A 2-Month Low On Study Results
www.rttnews.com - October 3 at 10:23 AM
Seres Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : MCRB-US : October 3, 2017Seres Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : MCRB-US : October 3, 2017
finance.yahoo.com - October 3 at 10:23 AM
How Should You Think About Seres Therapeutics Inc’s (MCRB) Risks?How Should You Think About Seres Therapeutics Inc’s (MCRB) Risks?
finance.yahoo.com - October 2 at 10:20 PM
Seres Therapeutics, Inc. (MCRB) Stock Rating Reaffirmed by Cowen and CompanySeres Therapeutics, Inc. (MCRB) Stock Rating Reaffirmed by Cowen and Company
www.americanbankingnews.com - October 2 at 9:32 PM
Seres Therapeutics (MCRB) Says Its Extremely Pleased with ... - StreetInsider.comSeres Therapeutics (MCRB) Says It's 'Extremely Pleased' with ... - StreetInsider.com
www.streetinsider.com - October 2 at 5:17 PM
Rigel Rises on Update on FDA Review of Bleeding Disorder TreatmentRigel Rises on Update on FDA Review of Bleeding Disorder Treatment
www.thestreet.com - October 2 at 11:59 AM
Seres Therapeutics Reports Positive Topline Results from SER-287 Phase 1b Study in Patients with Ulcerative ColitisSeres Therapeutics Reports Positive Topline Results from SER-287 Phase 1b Study in Patients with Ulcerative Colitis
www.nasdaq.com - October 2 at 11:59 AM
Seres Therapeutics stock drops 19% on clinical trial resultsSeres Therapeutics stock drops 19% on clinical trial results
www.marketwatch.com - October 2 at 11:59 AM
CORRECTING and REPLACING Seres Therapeutics Reports Positive Topline Results from SER-287 Phase 1b Study in Patients with Ulcerative ColitisCORRECTING and REPLACING Seres Therapeutics Reports Positive Topline Results from SER-287 Phase 1b Study in Patients with Ulcerative Colitis
finance.yahoo.com - October 2 at 11:59 AM
 Analysts Expect Seres Therapeutics, Inc. (MCRB) Will Announce Quarterly Sales of $23.01 Million Analysts Expect Seres Therapeutics, Inc. (MCRB) Will Announce Quarterly Sales of $23.01 Million
www.americanbankingnews.com - September 30 at 9:50 AM
Seres Therapeutics Is Hiding A Volatile Catalyst - Seeking AlphaSeres Therapeutics Is Hiding A Volatile Catalyst - Seeking Alpha
seekingalpha.com - September 24 at 1:12 AM
ETFs with exposure to Seres Therapeutics, Inc. : September 22, 2017ETFs with exposure to Seres Therapeutics, Inc. : September 22, 2017
finance.yahoo.com - September 23 at 8:05 AM
Seres Therapeutics, Inc. :MCRB-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017Seres Therapeutics, Inc. :MCRB-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017
finance.yahoo.com - September 21 at 6:00 PM
Seres Therapeutics, Inc. (MCRB) Receives Average Recommendation of "Buy" from BrokeragesSeres Therapeutics, Inc. (MCRB) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - September 12 at 4:40 AM
 Analysts Anticipate Seres Therapeutics, Inc. (MCRB) Will Post Quarterly Sales of $23.01 Million Analysts Anticipate Seres Therapeutics, Inc. (MCRB) Will Post Quarterly Sales of $23.01 Million
www.americanbankingnews.com - September 11 at 10:50 AM
-$0.24 EPS Expected for Seres Therapeutics, Inc. (MCRB) This Quarter-$0.24 EPS Expected for Seres Therapeutics, Inc. (MCRB) This Quarter
www.americanbankingnews.com - September 9 at 11:50 AM
Seres Therapeutics to Present at the Baird 2017 Global Healthcare ConferenceSeres Therapeutics to Present at the Baird 2017 Global Healthcare Conference
finance.yahoo.com - September 1 at 3:52 AM
Seres Therapeutics, Inc. (MCRB) Earns Buy Rating from Cantor FitzgeraldSeres Therapeutics, Inc. (MCRB) Earns Buy Rating from Cantor Fitzgerald
www.americanbankingnews.com - August 31 at 7:34 PM
Seres Therapeutics (MCRB) & Ophthotech Corporation (OPHT) Head to Head ComparisonSeres Therapeutics (MCRB) & Ophthotech Corporation (OPHT) Head to Head Comparison
www.americanbankingnews.com - August 30 at 12:22 AM
FY2017 Earnings Forecast for Seres Therapeutics, Inc. (NASDAQ:MCRB) Issued By Cantor FitzgeraldFY2017 Earnings Forecast for Seres Therapeutics, Inc. (NASDAQ:MCRB) Issued By Cantor Fitzgerald
www.americanbankingnews.com - August 10 at 10:42 AM
Leerink Swann Research Analysts Increase Earnings Estimates for Seres Therapeutics, Inc. (NASDAQ:MCRB)Leerink Swann Research Analysts Increase Earnings Estimates for Seres Therapeutics, Inc. (NASDAQ:MCRB)
www.americanbankingnews.com - August 7 at 7:40 AM
Seres Therapeutics, Inc. (NASDAQ:MCRB) Expected to Post Quarterly Sales of $3.00 MillionSeres Therapeutics, Inc. (NASDAQ:MCRB) Expected to Post Quarterly Sales of $3.00 Million
www.americanbankingnews.com - August 5 at 7:14 AM
HC Wainwright Increases Seres Therapeutics, Inc. (NASDAQ:MCRB) Price Target to $19.00HC Wainwright Increases Seres Therapeutics, Inc. (NASDAQ:MCRB) Price Target to $19.00
www.americanbankingnews.com - August 4 at 10:36 AM

Social Media

Financials

Chart

Seres Therapeutics (NASDAQ MCRB) Chart for Monday, November, 20, 2017
Loading chart…

This page was last updated on 11/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.